Pia Herbolsheimer
AstraZeneca (Netherlands)(NL)AstraZeneca (Japan)(JP)AstraZeneca (Poland)(PL)AstraZeneca (Spain)(ES)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, HER2/EGFR in Cancer Research, PARP inhibition in cancer therapy, Breast Cancer Treatment Studies, BRCA gene mutations in cancer
Most-Cited Works
- → Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study(2020)442 cited
- → Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study(2019)142 cited
- → An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)(2018)130 cited
- → BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).(2021)106 cited
- → Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)(2019)95 cited